Morepen Laboratories Q3 FY26 earnings call: Revenue & Margins
Q3 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹484Cr
- +6.8% YoY
- +17.5% QoQ
- Net profit
- ₹28Cr
- +3.7% YoY
- −31.7% QoQ
- Margin
- 10%
- +2 pp YoY
- +3 pp QoQ
Guidance rank: #77 of 87 in Pharmaceuticals & Biotechnology
See the sector's top 10 — free with your mobile number.
Based on Morepen Laboratories Ltd's Q3 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23). Quarterly EBITDA (Consolidated) Q3 FY26: Rs. 50 crores, up 42% YoY (Page 23).
From Morepen Laboratories Ltd's Q3 FY26 earnings-call transcript · updated 25 Sept 2026.
Revenue & Sales Performance
- Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23).
- Q3 FY26 standalone gross revenue: Rs. 462 crores, up 23% from Q3 FY25 Rs. 374 crores (Page 22).
- Medical Devices revenue Q3 FY26: Rs. 78 crores vs Rs. 73 crores in Q3 FY25, 6% growth (Page 19).
- BP Monitor revenue and other medical devices segments increased significantly, e.g., BP monitors 17.4% share (Page 20).
2 more points from Morepen Laboratories Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Morepen Laboratories Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Morepen Laboratories Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Morepen Laboratories Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Morepen Laboratories Ltd said on order book & pipeline — free account, 30 seconds.
Morepen Laboratories Ltd — Quarterly revenue & net profit
Morepen Laboratories Ltd Q3 FY26 results — key figures
| ₹ Cr | Q3 FY26 | Q3 FY25 | YoY | Q2 FY26 | QoQ |
|---|---|---|---|---|---|
| Revenue | 484 | 453 | +6.8% | 412 | +17.5% |
| Operating profit (EBITDA) | 46 | 36 | +27.8% | 31 | +48.4% |
| Operating margin | 10% | 8% | +2 pp | 7% | +3 pp |
| Profit before tax | 35 | 35 | 0% | 46 | -23.9% |
| Net profit (PAT) | 28 | 27 | +3.7% | 41 | -31.7% |
| EPS (₹) | 0.50 | 0.49 | +2% | 0.75 | -33.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹746 Cr, net profit ₹89 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Morepen Laboratories's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Natural Capsules (Q3 FY26)
Q3FY26 revenue from operations: ₹37.75 crore . Key investor presentation takeaways from Natural Capsules Ltd's Q3 FY26 investor presentation — and how it ranks
- Wanbury (Q3 FY26)
Q3FY26 Revenue from Operations: ₹162.45 Crore . Key investor presentation takeaways from Wanbury Ltd's Q3 FY26 investor presentation — and how it ranks against
- Gujarat Themis Biosyn (Q3 FY26)
43.37 crore, up 9.74% YoY from Rs. Key investor presentation takeaways from Gujarat Themis Biosyn Ltd's Q3 FY26 investor presentation — and how it ranks against
- Balaxi Pharma (Q3 FY26)
Q3 FY26 revenue: ₹72.54 crore, down marginally by 1% YoY from ₹73.29 crore in Q3 FY25 (Page 19). Key investor presentation takeaways from Balaxi Pharma's Q3 FY2
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Morepen Laboratories Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Morepen Laboratories Ltd Q3 FY26 results?
Q3 FY26 consolidated gross revenue: Rs. 488 crores, up 17% from Q3 FY25 Rs. 416 crores (Page 23). Quarterly EBITDA (Consolidated) Q3 FY26: Rs. 50 crores, up 42% YoY (Page 23).
What is Morepen Laboratories Ltd share price analysis?
Morepen Laboratories Ltd currently shows a neutral. The stock trades at a P/E of 56.4 with a market cap of ₹6,625 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Morepen Laboratories Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
